{
    "clinical_study": {
        "@rank": "33589", 
        "brief_summary": {
            "textblock": "The purpose of this study is to  determine whether BL-8040 is safe, tolerable and effective\n      in the mobilization of Hematopoietic Stem Cells (HSC) in healthy volunteers"
        }, 
        "brief_title": "A Phase I Study Evaluating Safety, Tolerability, PK and PD of BL-8040 for Stem Cell Mobilization in Healthy Volunteers", 
        "condition": "Mobilization of Hematopoietic Stem Cells (HSC) to Peripheral Blood (PB)", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy male subjects\n\n          -  BMI between 18 and 30 kg/m2 and Weight \u2265 60 Kg\n\n          -  Subjects must be either surgically sterilized (vasectomy), or if their partner is of\n             childbearing potential, must use two methods of contraception, one of which must be a\n             barrier method, from the first dose until 3 months after the last dose\n\n          -  Subject is able and willing to comply with the requirements of the protocol\n\n        Exclusion Criteria:\n\n          -  History of clinically significant disease\n\n          -  Any illness within the 4 weeks prior to the screening examination\n\n          -  Any history of alcohol and/or drug of abuse addiction and/or active / past (up to 2\n             years before screening) nicotine consumption\n\n          -  Clinically relevant deviation from normal in the physical examination and vital signs\n             at screening or baseline\n\n          -  Clinically relevant laboratory abnormalities identified at screening or baseline\n\n          -  Positive tests at screening for HIV I & II, hepatitis B and/or hepatitis C in both\n             parts or positive tests for Syphilis, HTLV I & II and Nucleic Acid Test (NAT) for HIV\n             and HBV\n\n          -  Positive test for urine drugs of abuse or by anamnesis (Barbiturates,\n             Benzodiazepines, Amphetamines, Opiates, Cocaine, Cannabinoids, Methadone,\n             Phencyclidine, and Tricyclic Antidepressants) and/or positive alcohol blood test\n\n          -  Subjects who have lost or donated in excess of 400 mL of blood within 3 months prior\n             to Day 1 of the study"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 25, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02073019", 
            "org_study_id": "BL-8040.02"
        }, 
        "intervention": {
            "intervention_name": "BL-8040", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "February 25, 2014", 
        "official_title": "A Phase I, Two Part Study Exploring the Safety, Tolerability, Pharmacodynamic and Pharmacokinetic Effect of Ascending Doses of BL-8040 in Healthy Subjects.", 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Israel: Ministry of Health", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Number of subjects with Adverse Events", 
            "safety_issue": "Yes", 
            "time_frame": "Up to 7 days after treatment comletion"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02073019"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "BioLineRx, Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "BioLineRx, Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "N/A", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}